期刊文献+

原发性输尿管癌预后的临床病理因素回顾性分析 被引量:2

Retrospective analysis of the clinical parameters and the prognostic factors with ureter transitional cell carcinoma patients
原文传递
导出
摘要 为了探讨输尿管癌临床病理因素对预后的影响,回顾性分析1995-01-2008-12接受手术治疗的原发输尿管癌51例患者的临床资料。在51例输尿管癌患者中,年龄(P=0.000)、临床分期(P=0.004)、组织学分级(P=0.000)及手术方式(P=0.048)与输尿管癌手术预后显著相关;性别(P=0.655)、肿瘤部位(P=0.245)及病理分级(P=0.092)与输尿管癌手术预后无关。临床分期中,浅表性输尿管癌(Ta~T1)10例(19.6%),浸润性输尿管癌(T2~T4)41例(80.4%),Kaplan-Meier法分析显示,浸润性输尿管癌生存率明显低于表浅输尿管癌,P=0.002。多因素Cox回归模型生存分析结果表明,临床分期(P=0.021)、组织学分级(P=0.001)、病理分级(P=0.048)及手术方式(P=0.039)是影响手术预后最显著的独立因素。初步研究结果提示,输尿管癌临床病理分级及手术方式与患者的生存相关,可作为患者的独立预后因素。 The objective of this study was to study the clinical parameters and prognostic factors in ureter transi- tional cell carcinoma(TCC) and their correlation with prognosis of patients. Between January 1995 and December 2008 51 TCC patients were treated, and the data was retrospectively analyzed. Univariate analysis identified that were associated with a significant outcome age(P = 0. 000), clinical stage(P = 0. 004), histologic type of lesion(P = 0. 000) and the way of surgical operation(P= 0. 048). The sex(P = 0. 655), location of primary lesion(P = 0. 245) and pathology type of lesion (P=0. 092) were not significantly associated with prognosis. The non-invasive TCC of the clinical stage was found in 10 patients(19.6%) and the invasive TCC in 41 patients(80.4%). Kaplan-Meier was applied to compare that the survival rate of invasive TCC was significantly longer than that of the non-invasive TCC(P= 0. 002). However, when the interac- tive effects of these factors were taken into account, the clinical stage(P= 0. 021), histologic type of lesion(P= 0. 001), pa- thology type of lesion(P=0. 048) and way of surgical operation(P=0. 039) were selected as the most significant prognos- tic factors in a multivariate analysis by using the Cox proportional hazard regression model. In conclusion,clinical stage, pathological grade and pattern of resection, are related with survival, and they are also independent prognosis factors of TCC.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第11期867-869,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 输尿管肿瘤/病理学 预后 多因素分析 回顾性研究 ureteral neoplasms/pathology prognosis multiplicity ~ retrospective studies
  • 相关文献

参考文献10

  • 1潘柏年,张争,刘玉立,郭应禄.174例原发性输尿管癌的临床分析[J].中华外科杂志,2004,42(23):1447-1449. 被引量:59
  • 2Olgac S, Mazumdar M, Dalbagin G,et al. Urothelial carcinoma of the renal pelvin:a clinicopathologic study of 130 cases[J]. Am J Surg Pathol, 2004,28(12) : 1545-1552.
  • 3Langner C, Hutterer G, Chromecki T, et al. pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract[J].Mod Pathol, 2006,19 (2) : 272-279.
  • 4Zigeuner R, Pummer K. Urothelial carcinoma of the upper urina- ry tract :surgical approach and prognostic factors[J].Eur Urol, 2008,53(4):720- 731.
  • 5Ching CL, Tu HC, Wen JW, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwan Residents patients[J]. Eur Urol, 2008, 54(4) :1127-1135.
  • 6关有彦,李宁忱,周利群,何志嵩,李鸣,那彦群.输尿管癌预后相关因素的临床研究[J].中华外科杂志,2007,45(18):1260-1263. 被引量:5
  • 7张秀丽,王乃玉,王朝晖,吕申,李梅.p53、C-erbB-2及nm23在肾盂输尿管癌中的表达特点及其意义[J].现代肿瘤医学,2009,17(3):519-521. 被引量:2
  • 8Hall MC,Womack S, Sagalowsky AI, et al. Prognostic factors recurrence,and survival in transitional cell carcinoma of the up per urinary tract:a 30-year experience in 252 patients[J]. Urolo gy,1998,52(4) :594-601.
  • 9马德年,迟学成,宋光州.肾盂及输尿管肿瘤的临床特点与治疗分析[J].中华肿瘤防治杂志,2010,17(18):1489-1490. 被引量:5
  • 10吴阶平.泌尿外科学[M].济南:山东科学技术出版社,1997.208-210.

二级参考文献27

  • 1孔垂泽,刘同才,张铭铮,王立忠,温强,李书章,李芳,孙志熙,任玉鹏.肾盂输尿管癌中P53表达的临床意义[J].中华泌尿外科杂志,1995,16(10):609-611. 被引量:5
  • 2Kirkali Z , Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis[ J]. Crit Rev Oncol Hematol ,2003,47(2) :155 -169.
  • 3Sarkis AS, Dalbagni G, Gordon C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression[ J]. J Nat Cancer Inst, 1993,85:53.
  • 4Slaton JW, Benedict WF, Dinney CP. p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy [ J]. Urology, 2001, 57:852-859.
  • 5Keeley FX, JR, Bibbo M, et al. Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol,1997, 157:1560-1565.
  • 6Tawfiek ER, Bagley DH. Upper-tract transitional cell carcinoma. Urology,1997,50:321-329.
  • 7Hall MC, Womack JS, Roehrborn CG, et al. Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, suivival and impact of postoperative adjuvant radiotherapy. J Urol, 1998,160:703-706.
  • 8Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer, 1988, 62:2016-2020.
  • 9Mills IM, Laniado ME, Patel A. The role of endoscopy in the management of patients with upper urinary tract transitional cell carcinoma . BJU Int, 2001, 87:150-162.
  • 10Planz B, George R, Adam G, et al. Computed tomography for detection and staging of transitional cell carcinoma of the upper urinary tract. Eur Urol, 1995,27:146-150.

共引文献79

同被引文献18

  • 1孔垂泽,刘奔,李振华,杨绍波,孙志熙.预防肾盂输尿管癌术后再发膀胱癌的手术方法研究[J].中华泌尿外科杂志,2006,27(4):250-252. 被引量:23
  • 2Roupret M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell car- cinomas: 2011 update[J]. Eur Urol ,2011,59(4) :584 -594.
  • 3Zini L, Perrotte P, Capitanio U, et al. Radical versus partial ne- phrectomy: effect on overall and noncancer mortality[J]. Cancer, 2009,115(7) :1465 - 1471.
  • 4Smith P, Mandel J, Raman JD. Conservative nephron- sparing treatment of upper - tract tunlors[ J]. Curt" Urol Rep ,2013,14 (2) :102 - 108.
  • 5Colin P, Ouzzane A, Pignot G, et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterecto- my in urothelial carcinomas of the upper urinary tract : results from a large French multicentre study [ J ]. BJU Int , 2012,110 ( 8 ) : 1134 - 1141.
  • 6Gadzinski AJ, Roberts WW, Faerber G J, et al. Long - term out- comes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma[ J ]. J Urol ,2010,183 (6) :2148 -2153.
  • 7Roupret M, Babjuk M, Comperat E, et al. European guidelines on upper tract urothelial carcinomas : 2013 update[ J ]. Eur Urol, 2013,63(6) :1059 - 1071.
  • 8Cowan NC. CT urography for hematuria[ J]. Nat Rev Urol,2012, 9:218 - 226.
  • 9Rojas CP, Castle SM, Llanos CA, et al. Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma[ J]. Urol Oncol,2013,31 : 1696 - 1700.
  • 10Lane BR, Smith AK, Larson BT, et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy [ J 1. Cancer, 2010,116 ( 12 ) :2967 - 2973.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部